Skip to main content
Cipher Pharmaceuticals Inc. logo

Cipher Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · CPHRF ISIN · CA17253X1050 LEI · 213800T44AN9XSAOY605 TSX Manufacturing
Open in API
Filings indexed 165 across all filing types
Latest filing 2025-05-21 Proxy Solicitation & In…
Country CA Canada
Listing TSX CPHRF

About Cipher Pharmaceuticals Inc.

https://www.cipherpharma.com/

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company focused on acquiring, marketing, and managing a diversified portfolio of commercial and pipeline products, primarily within the dermatology sector. The company seeks to fulfill unmet medical needs by acquiring best-in-class products and managing the necessary clinical development and regulatory processes. Its portfolio includes key commercial products such as Epuris (isotretinoin), an oral retinoid indicated for the treatment of acne. Cipher's strategy involves continually evaluating businesses with commercial products for merger or acquisition opportunities to expand its offerings.

Recent filings

Filing Released Lang Actions
Notice of meeting - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled “Notice of Annual and Special Meeting of Shareholders,” sets a record date, meeting agenda (election of directors, appointment of auditor, share plan approval, etc.), and describes proxy voting procedures and accompanying materials (management information circular). This is a solicitation of shareholder votes and proxy information rather than the full annual report or management discussion, fitting the Proxy Solicitation & Information Statement category.
2025-05-21 English
Management information circular - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled “Notice of Annual and Special Meeting of Shareholders and Management Information Circular,” provides detailed proxy voting instructions (how to vote, appoint proxyholders, revocation), agenda items (director elections, auditor reappointment, share plan approvals), executive compensation disclosures, corporate governance charters, and is sent to shareholders to solicit votes at the AGM. This matches the Proxy Solicitation & Information Statement category.
2025-05-21 English
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a corporate press release presenting Cipher Pharmaceuticals’ first quarter 2025 financial highlights, management commentary, and key metrics, with an announcement of a conference call. It summarizes revenue, EBITDA, cash flow, and corporate updates, but directs readers to the company’s website or SEDAR+ for the full financial statements and MD&A. This format—initial announcement of quarterly results—is characteristic of an Earnings Release (ER), not a full interim report or MD&A. Q1 2025
2025-05-08 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109F2 “Certification of Interim Filings” under Canadian securities rules, consisting of management’s certificate regarding the interim financial report and interim MD&A for the period ended March 31, 2025. It is not the interim report itself (IR), nor an announcement of its publication (RPA), nor an audit opinion (AR). As there is no specific category for officer certifications, this is best classified under the general regulatory filings category (RNS).
2025-05-08 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is the CFO’s certification under Canadian National Instrument 52-109 (“Form 52-109F2”), certifying the issuer’s interim financial report and interim MD&A for the quarter ended March 31, 2025. It is not the interim report itself (which would be an IR) but rather a standalone regulatory certification form that accompanies those interim filings. There is no dedicated category for certification forms, so this falls under the general “Regulatory Filings” fallback.
2025-05-08 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled "Management's Discussion and Analysis" for the three months ended March 31, 2025, and contains detailed narrative analysis of operating results, forward-looking statements, market data, business strategy, and key performance tables. It is prepared under IFRS and IAS 34 for interim reporting, but consists solely of the MD&A section rather than the full financial statements. This matches the definition for Management Reports (MDA): management’s detailed explanation of financial results, business trends, and outlook, rather than a simple earnings release or the entire interim report.
2025-05-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.